Time to Next Treatment in Patients with Chronic Lymphocytic Leukemia Initiating First-Line Ibrutinib or Acalabrutinib
Ryan Jacobs, Xiaoxiao Lu, Bruno Émond, Laura Morrison, Frédéric Kinkead, Patrick Lefèbvre, Marie‐Hélène Lafeuille, Wasiulla Khan, Linda Wu, Zaina P. Qureshi, Moshe Levy
Abstract
Aim: To investigate real-world time to next treatment in patients with chronic lymphocytic leukemia initiating first-line (1L) ibrutinib or acalabrutinib. Materials & methods: US specialty pharmacy electronic medical records (11/21/2018–4/30/2022) were used; patients initiated 1L on/after 11/21/2019 (acalabrutinib approval). Results: Among 710 patients receiving ibrutinib, 5.9% initiated next treatment (mean time to initiation = 9.2 months); among 373 patients receiving acalabrutinib, 7.5% initiated next treatment (mean time to initiation = 5.9 months). Adjusting for baseline characteristics, acalabrutinib-treated patients were 89% more likely to initiate next treatment (hazard ratio = 1.89; p = 0.016). Conclusion: This study addresses a need for real-world comparative effectiveness between 1L ibrutinib and acalabrutinib and shows that next treatment (a clinically meaningful measure for real-world progression) occurred less frequently with 1L ibrutinib.